709 / 1835
90
Y Ibritumomab tiuxetan
:
Active in Chemorefractory NHL
Chemorefractory
P
= 0.022
Chemosensitive
P
= 0.394
International Workshop
Response Criteria (%)
0
20
40
60
80
100
73%
42%
71%
83%
ZEVALIN (
n
=33)
ZEVALIN (
n
=35)
Rituxan
(
n
=35)
Rituxan
(
n
=31)
Randomized Phase 3 Trial